News & Events about Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference PR Newswire WASHINGTON, Jan. 6, 2023 WASHINGTON, Jan. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq...
Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety PR Newswire WASHINGTON, Dec. 2, 2022 WASHINGTON...
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences PR Newswire WASHINGTON, Nov. 8, 2022 WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA...
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera PR Newswire WASHINGTON, Oct. 21, 2022 WASHINGTON...
Ticker Report
3 months ago
Equities researchers at StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA Get Rating) in a research report issued on Wednesday. The firm set a buy rating on the biopharmaceutical companys stock. Vanda Pharmaceuticals Stock Performance Shares ...